Low-molecular heparins in the treatment of non-iT elevation acute coronary syndrome


Cite item

Full Text

About the authors

A L Komarov

E P Panchenko

References

  1. АСС/АНА Guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology / American Heart Association Task Force On Practice Guidelines (Committee on Management of Acute Myocardial Infarction) J. Am. Coll. Cardiol. 1996; 28: 1328-1428.
  2. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. 2002; 324: 71-86.
  3. Fuster V., Fallon J. Т., Badimon J. J., Nemerson Y. The unstable atherosclerotic plaque: clinical significance and therapeutic intervention, Thromb. and Haemost. 1997; 78 (1): 247-255.
  4. Ageno W., Turpie A. G. G. New advances in the management of acute coronary syndromes: Low-molecular-weight heparins. Can. Med. Assoc. J. 2002; 166 (7): 919-924.
  5. Hirsh J. et al. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S-94S.
  6. Theroux P., Ouimet H., McCans J. et al. Aspirin, heparin, or both to treat acute unstable angina. N. Engl. J. Med. 1988; 319: 1105-1111.
  7. RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-830.
  8. Theroux P., Waters D., Lam J. et al. Reactivation of unstable angina after the discontinuation of heparin. N. Engl. J. Med. 1992; 327: 141-145.
  9. ACC/AHA. 2002 Guideline update for the management of patients with unstable angina/non-iST-segment elevation. J. Am. Coll. Cardiol. 2000; 36: 970-1056.
  10. Gurflnkel E. P., Manos E. J., Mejail R. I. et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J. Am. Coll. Cardiol. 1995; 26: 313-318.
  11. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability incoronary artery disease. Lancet 1996; 347: 561-568.
  12. Serneri G. G., Medesti P. A., Gensini G. F. et al. Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Lancet 1995; 345: 1201-1204.
  13. Lindahl В., Venge P., Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J. Am. Coll. Cardiol. 1997; 29: 43-48.
  14. Klein W., Buchwald A., Hillis S. E. et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997; 96: 61-68.
  15. Fragmin and fast revascularisation during Instability in coronary artery disease investigators. Long-term low-molecularmass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 701-707.
  16. Fragmin and fast revascularisation during Instability in Coronary artery disease investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 708-715.
  17. Wallentin L., Lagerqvist В., Husted S. et al. Outcome at one year after an invasive compared with a non-invasive strategy in unstable coronary artery disease: the FRISC II invasive randomized trial. Lancet 2000; 356: 9-16.
  18. FRAXIS study group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction. FRAX. I. S. (FRAXiparine in Ischaemic Syndrome). Eur. Heart J. 1999; 20: 1553-1562.
  19. Cohen M., Demers C., Gurfmkel E. P. et al. A comparison of lowmolecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N. Engl. J. Med. 1997; 337: 447-452.
  20. Antman E. M., McCabe С. Е., Gurfmkel E. P. et al. Enoxaparin prevents death and cardiac ischemic events in unstable anginanon-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation 1999; 100: 1593-1601.
  21. James S., Armstrong P., Calif R. et al. Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. Eur. Heart J. 2002; 23: 1538-1545.
  22. Kereiakes D. J., Kleiman N. S., Fry E. et al. Dalteparin in combination with abciximab during percutaneous coronary intervention.Am. Heart J. 2001; 141 (3): 348-352.
  23. Wong G. C., Giugliano R. P., Antman E. M. Use of low-molecular weight heparins in the management of acute coronary syndromes and percutaneous coronary intervention. J. A. M. A. 2003; 289: 331-342.
  24. Ferguson J. J. The use of enoxaparin and Ilb/IIIa antagonists in acute coronary syndromes; including PCI: final results of NICE 3 study. J. Am. Coll. Cardiol. 2001; 37 (suppl. A): 365A.
  25. Kereiakes D. J., Grines C., Fry E. et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J. Invasive Cardiol. 2001; 13: 272-278.
  26. Wallentin L., Wilcox R. G., Weaver W. D. et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. THE LANCET Published online September 1, 2003
  27. <http://image.thelancet.com/extras/>03art6477web.pdf

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies